Mallinckrodt enters $1.35B credit facility to fund Endo acquisition

Keenova Therapeutics plc

$1.2 billion term loan and $150 million revolving credit facility dated July 31, 2025.
Credit agreement entered simultaneously with the closing of the acquisition of Endo, Inc.
Facilities arranged by Goldman Sachs Bank USA; Wilmington Savings Fund Society as agent.
Borrower is MEH, Inc.; guaranty provided by parent ST 2020, Inc.
Proceeds used to finance the Endo acquisition and related transaction expenses.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.